How does PMA differ from 510(k)?

PMA demonstrates safety and effectiveness for high-risk (often Class III) devices, typically with clinical evidence. A 510(k) shows substantial equivalence to a predicate for lower-risk devices.

Do I always need clinical trials for a PMA?

Clinical studies are commonly required for PMA. FDA expects valid scientific evidence; the exact evidence type depends on device risk, indications, and feasibility.

Can FDA require post-approval studies?

Yes. FDA may mandate post-approval studies to assess long-term performance, rare events, or specific sub-populations after approval.

How are changes handled after approval?

Through PMA supplements (Panel-Track, 180-Day, Real-Time, Special CBE, and 30-Day/135-Day) depending on the scope and risk of the change.

Will FDA inspect manufacturing before approval?

FDA may perform a pre-approval inspection to verify manufacturing controls are adequate for commercial release.

Do expedited programs help PMA review?

Yes. Programs such as Breakthrough Devices can enable prioritized interaction and more efficient review while maintaining statutory evidence requirements.

« Back to Glossary Index

Premarket Approval (PMA)

Q: When is PMA required?

PMA is required for Class III, high-risk devices or when no predicate exists for a 510(k) or De Novo submission.

Q: How long does FDA take to review a PMA?

The statutory review timeline is 180 days, but reviews are often extended due to deficiency letters and requests for additional data.

Q: What is the difference between PMA and 510(k)?

PMA requires direct clinical and non-clinical evidence of safety and effectiveness, while 510(k) demonstrates substantial equivalence to an existing predicate.

Q: What are PMA supplements?

They are additional submissions required for changes to approved devices, including Panel-Track, 180-Day, Real-Time, Special CBE, and 30-Day Notice.

Q: Can a PMA be modular?

Yes, under 21 CFR 814.106, a Modular PMA allows manufacturers to submit modules before the complete application for staged FDA review.

Premarket Approval (PMA) is the U.S. FDA’s most rigorous medical device regulatory pathway, required for Class III, high-risk, and novel devices that support or sustain human life, prevent impairment of health, or present a potential unreasonable risk of illness or injury. Unlike the 510(k) pathway, which demonstrates substantial equivalence to a predicate device, PMA requires manufacturers to provide direct evidence of safety and effectiveness through comprehensive non-clinical and clinical data.

Class III / high-riskFDA 21 CFR 814Clinical evidence required

What a PMA includes

Device description, indications for use, and intended purpose.
Non-clinical testing: bench, biocompatibility, sterilization, electrical/EMC, software validation.
Clinical data: pivotal trial(s), IDE reports, statistical analyses.
Manufacturing information: quality system details (ISO 13485/QSR compliance).
Labeling and Instructions for Use (IFU).
Risk/benefit analysis and justification of safety and effectiveness.
Post-approval study commitments, if required by FDA.
Optional: Modular PMA approach available (21 CFR 814.106) allowing staged submission of sections before the complete application.

PMA Review Process

Application acceptance check (filing review).
Interactive review: deficiency letters, requests for additional information.
Advisory Panel meeting may be required for high-profile or novel devices.
FDA review clock: Statutory 180 days, though extended if major deficiencies or data requests are issued.
Approval order, approvable with conditions, or denial.

PMA Supplements (changes to approved devices)

Panel-Track Supplement: Major change in intended use or indications (advisory panel review required).
180-Day Supplement: Significant design, labeling, or manufacturing changes needing full FDA review.
Real-Time Supplement: Minor changes reviewed in less time through direct FDA–sponsor discussion.
Special Supplement—Changes Being Effected (CBE): Immediate implementation allowed with 30-day FDA notification, or 30-day wait depending on change type.
30-Day Notice: Manufacturing process changes; FDA may convert to a 180-Day Supplement if more substantive review is needed.

PMA vs. 510(k) vs. De Novo

PMA: High-risk; full demonstration of safety/effectiveness; longest and most resource-intensive.
510(k): Moderate-risk; substantial equivalence to predicate device; generally faster.
De Novo: Novel low-to-moderate-risk devices without predicate; creates a new classification.

Quick FAQ

When is PMA required?

For high-risk Class III devices or when no predicate device exists to support a 510(k) or De Novo submission.

How long does FDA take to review a PMA?

The statutory review clock is 180 days, but FDA frequently extends this through deficiency letters and additional data requests.

What is the difference between PMA and 510(k)?

PMA requires direct evidence of safety and effectiveness (often clinical trials). 510(k) requires showing substantial equivalence to a predicate device.

What are PMA supplements?

Formal submissions required for post-approval changes (Panel-Track, 180-Day, Real-Time, Special CBE, 30-Day Notice).

Can a PMA be modular?

Yes. A Modular PMA allows sections (modules) to be submitted and reviewed before the complete application, improving efficiency (21 CFR 814.106).

PMA vs De Novo vs 510(k) — at a glance

PMAClass III / high-risk

Standard: Safety & effectiveness (often clinical)
When: No predicate or PMA-listed type
Evidence: Robust non-clinical + clinical
Timeline: Longest; panel possible
Changes: PMA supplements (Panel-Track, 180-Day, Real-Time, Special CBE, 30-Day Notice)

De NovoClass I/II novel

Standard: Reasonable assurance of safety & effectiveness
When: No predicate, low-to-moderate risk
Evidence: Risk-based; may include clinical
Outcome: Creates new classification & special controls
Future: Can serve as predicate for 510(k)s

510(k)Class II (most)

Standard: Substantial equivalence to predicate
When: Predicate exists; same intended use
Evidence: Bench/biocomp/EMC; clinical rarely
Timeline: Generally faster than De Novo/PMA
Variants: Traditional, Special, Abbreviated

Pick PMA when the device is high-risk or explicitly PMA-required.
Pick De Novo when the device is novel with low-to-moderate risk and no suitable predicate.
Pick 510(k) when a valid predicate exists and you can show substantial equivalence.